Published in:
Open Access 01-12-2022 | Chronic Inflammatory Bowel Disease | Research
Polygenic risk and causal inference of psychiatric comorbidity in inflammatory bowel disease among patients with European ancestry
Published in: Journal of Translational Medicine | Issue 1/2022
Login to get accessAbstract
Background
Approximately 40% of persons with inflammatory bowel disease (IBD) experience psychiatric comorbidities (PC). Previous studies demonstrated the polygenetic effect on both IBD and PC. In this study, we evaluated the contribution of genetic variants to PC among the IBD population. Additionally, we evaluated whether this effect is mediated by the expression level of the RBPMS gene, which was identified in our previous studies as a potential risk factor of PC in persons with IBD.
Materials and methods
The polygenic risk score (PRS) was estimated among persons with IBD of European ancestry (n = 240) from the Manitoba IBD Cohort Study by using external genome-wide association studies (GWAS). The association and prediction performance were examined between the estimated PRS and PC status among persons with IBD. Finally, regression-based models were applied to explore whether the imputed expression level of the RBPMS gene is a mediator between estimated PRS and PC status in IBD.
Results
The estimated PRS had a significantly positive association with PC status (for the highest effect: P-value threshold = 5 × 10–3, odds ratio = 2.0, P-value = 1.5 × 10–5). Around 13% of the causal effect between the PRS and PC status in IBD was mediated by the expression level of the RBPMS gene. The area under the curve of the PRS-based PC prediction model is around 0.7 at the threshold of 5 × 10–4.
Conclusion
PC status in IBD depends on genetic influences among persons with European ancestry. The PRS could potentially be applied to PC risk screening to identify persons with IBD at a high risk of PC. Around 13% of this genetic influence could be explained by the expression level of the RBPMS gene.